| |
Latest 10 SEC filings (by transaction date) for RXRX within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 18/24 | Apr 17/24 | Secora Michael | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -37,500 | |
Apr 18/24 | Apr 17/24 | Secora Michael | Direct Ownership | Class A Common Stock | S - Open market or private sale | -23,124 | $7.58 |
Apr 18/24 | Apr 17/24 | Secora Michael | Direct Ownership | Class A Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 37,500 | $2.22 |
Apr 18/24 | Apr 16/24 | Borgeson Blake | Direct Ownership | Class A Common Stock | S - Open market or private sale | -11,447 | $7.66 |
Apr 18/24 | Apr 16/24 | Secora Michael | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -37,500 | |
Apr 18/24 | Apr 16/24 | Secora Michael | Direct Ownership | Class A Common Stock | S - Open market or private sale | -25,000 | $7.67 |
Apr 18/24 | Apr 16/24 | Secora Michael | Direct Ownership | Class A Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 37,500 | $2.22 |
Apr 5/24 | Apr 4/24 | Gibson Christopher | Indirect Ownership | Class B Common Stock | C - Conversion | -25,000 | |
Apr 5/24 | Apr 4/24 | Gibson Christopher | Indirect Ownership | Class A Common Stock | S - Open market or private sale | -25,000 | $9.02 |
Apr 5/24 | Apr 4/24 | Gibson Christopher | Indirect Ownership | Class A Common Stock | C - Conversion | 25,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for RXRX within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 18/24 | Apr 16/24 | Borgeson Blake | Direct Ownership | Class A Common Stock | S - Open market or private sale | -11,447 | $7.66 |
Apr 18/24 | Apr 17/24 | Secora Michael | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -37,500 | |
Apr 18/24 | Apr 16/24 | Secora Michael | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -37,500 | |
Apr 18/24 | Apr 17/24 | Secora Michael | Direct Ownership | Class A Common Stock | S - Open market or private sale | -23,124 | $7.58 |
Apr 18/24 | Apr 17/24 | Secora Michael | Direct Ownership | Class A Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 37,500 | $2.22 |
Apr 18/24 | Apr 16/24 | Secora Michael | Direct Ownership | Class A Common Stock | S - Open market or private sale | -25,000 | $7.67 |
Apr 18/24 | Apr 16/24 | Secora Michael | Direct Ownership | Class A Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 37,500 | $2.22 |
Apr 5/24 | Apr 4/24 | Gibson Christopher | Indirect Ownership | Class B Common Stock | C - Conversion | -25,000 | |
Apr 5/24 | Apr 3/24 | Gibson Christopher | Indirect Ownership | Class B Common Stock | C - Conversion | -25,000 | |
Apr 5/24 | Apr 4/24 | Gibson Christopher | Indirect Ownership | Class A Common Stock | S - Open market or private sale | -25,000 | $9.02 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |